![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1297797
¼¼°èÀÇ ¼¼Æ÷ ¼±º° ½ÃÀå(2023-2030³â)Global Cell Sorting Market - 2023-2030 |
¼¼°è ¼¼Æ÷ ¼±º° ½ÃÀåÀº 2022³â 2¾ï 3,650¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2030³â¿¡´Â 3¾ï 8,980¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼Æ÷ ¼±º° ¼¼°è ½ÃÀåÀº 2023-2030³â ¿¹Ãø ±â°£ µ¿¾È 6.6%ÀÇ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼Æ÷ ¼±º°Àº ¿¬±¸, ÀÓ»ó Áø´Ü ¹× Ä¡·á¿¡¼ ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµË´Ï´Ù. Áٱ⼼Æ÷³ª ¼øÈ¯ Á¾¾ç ¼¼Æ÷¿Í °°Àº Èñ±ÍÇÑ ¼¼Æ÷±ºÀ» ºÐ¸®ÇÏ¿© Ãß°¡ ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, ¼¼Æ÷ ±â¹Ý ÀǾàǰ °³¹ßÀ̳ª ¸é¿ª ¼¼Æ÷ Áý´Ü ¿¬±¸¿Í °°Àº Ä¡·áÀû ¿ëµµ·Î ƯÁ¤ ¼¼Æ÷ À¯ÇüÀ» ½±°Ô Á¤Á¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.
±×·¯³ª ³ôÀº Àåºñ °¡°Ý, ¾ö°ÝÇÑ ±ÔÁ¦, ¼÷·ÃµÈ Àη ºÎÁ·, ½ÅÈï±¹¿¡¼ÀÇ ¼¼Æ÷ ¼±º° ±â¼ú¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ· µîÀÌ ¼¼Æ÷ ¼±º° ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¹Ì±¹ ¼ºÀÎÀÇ 60% °¡±îÀ̰¡ Àû¾îµµ ÇÑ °¡Áö ÀÌ»óÀÇ ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. ¹Ì±¹ÀÇ ÁÖ¿ä »ç¸Á ¿øÀÎÀº ´ç´¢º´, ¾Ï, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÔ´Ï´Ù. ½ÉÀ庴, ¾Ï, ³úÁ¹Áß, ¸¸¼ºÆó¼â¼ºÆóÁúȯ, ´ç´¢º´Àº Àüü »ç¸Á¿øÀÎÀÇ 3ºÐÀÇ 2 ÀÌ»óÀ» Â÷ÁöÇÕ´Ï´Ù.
CDC¿¡ µû¸£¸é, ¹Ì±¹ ¿¬°£ ÀÇ·áºñ 3Á¶ 8,000¾ï ´Þ·¯ÀÇ 90%°¡ ¸¸¼º Áúȯ ¹× Á¤½Å °Ç° ¹®Á¦¸¦ °¡Áø »ç¶÷µé¿¡°Ô¼ ¹ß»ýÇϸç, Partnership to Fight Chronic DiseaseÀÇ ÃÖ±Ù º¸°í¼¿¡ µû¸£¸é, 2030³â±îÁö ¹Ì±¹¿¡¼ °¡Àå ¸¹ÀÌ ¹ß»ýÇÏ´Â 7´ë ¸¸¼º Áúȯ¿¡ ´ëÇÑ ¸¸¼ºÁúȯÀÇ Ä¡·áºñ¿ëÀº ¿¬°£ 2Á¶ ´Þ·¯, 1Àδç 8,600´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. º¸°í¼¿¡ µû¸£¸é, À¯ÇØÇÑ ÇൿÀ» ÁÙÀÌ¸é ¿¬°£ 110¸¸ ¸íÀÇ »ç¸ÁÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù.
¹Ì±¹ ÃÖ´ë »ê¾÷ Áß ÇϳªÀÎ ¹ÙÀÌ¿ÀÀǾàǰÀº ¿¬°£ ¼ö½Ê¾ï ´Þ·¯ÀÇ °¡Ä¡°¡ ÀÖÀ¸¸ç, ¹Ì±¹ °æÁ¦¿Í ±× Á¦Ç°À» »ç¿ëÇϴ ȯÀÚ¿¡°Ô ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ »ç¾÷Àº CDMO ¹ÙÀÌ¿À·ÎÁ÷½º ±â¾÷ÀÇ ÃâÇöÀ¸·Î ÀÌÀüº¸´Ù ´õ ºü¸£°Ô ÀǾàǰÀ» »ý»êÇÒ ¼ö ÀÖ°Ô µÇ¸é¼ ¾öû³ ¼ºÀåÀ» °æÇèÇϰí ÀÖ½À´Ï´Ù.
ÀÌ »ê¾÷ÀÇ È®ÀåÀº ¼¼°è Àα¸ÀÇ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¼¼°è Àα¸ÀÇ ¼ö¿ä´Â ¹ÙÀÌ¿ÀÀǾàǰ »ç¾÷¿¡ ´ëÇÑ ¾Ð·ÂÀ» ³ôÀ̰í ÀÖÁö¸¸, µ¿½Ã¿¡ ´õ ¸¹Àº ÅõÀÚ¸¦ À¯Ä¡ÇÏ°í ¼öÀͼºÀ» ³ôÀ̰í È®ÀåÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù.
°³ÀÎÈ ÀÇ·á´Â Áø´Ü, Åõ¾à, ¿¹¹æ¿¡ ´ëÇÑ '°³ÀÎ ¸ÂÃãÇü' Á¢±Ù ¹æ½ÄÀ» ¹Ù²Ü ¼ö ÀÖ½À´Ï´Ù. ȯÀÚº° Ư¼º¿¡ ±â¹ÝÇÑ Ç¥ÀûÄ¡·á°¡ ¸ÂÃãÀÇ·áÀÇ ¸ñÇ¥ÀÔ´Ï´Ù. ¸ÂÃãÇü Ä¡·á¸¦ À§ÇØ Æ¯Á¤ ¼¼Æ÷ À¯ÇüÀ» ½Äº°ÇÏ°í ºÐ¸®ÇÏ´Â °ÍÀº ¼¼Æ÷ ¼±º° ±â¼ú¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÀÇ·á°¡ ¼ºÀåÇÔ¿¡ µû¶ó ¼¼Æ÷ ¼±º° ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
COVID-19 ÆÒµ¥¹ÍÀº ¼¼Æ÷ ¼±º° ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. COVID-19°¡ ¸é¿ª ¹ÝÀÀÀÇ º¯µ¿¼º°ú ´Ù¾çÇÑ ¼¼Æ÷ À¯Çü¿¡ ¹ÌÄ¡´Â ¿µÇâÀº ¼¼Æ÷ ¼±º°¸¦ Æ÷ÇÔÇÑ ´ÜÀÏ ¼¼Æ÷ ºÐ¼® ±â¼úÀ» ÅëÇØ ±¤¹üÀ§ÇÏ°Ô ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ÆÒµ¥¹ÍÀº °³º° ¼¼Æ÷ÀÇ Æ¯¼º°ú ¹ÝÀÀ¿¡ ´ëÇÑ ÀÌÇØÀÇ Çʿ伺À» °Á¶ÇÔÀ¸·Î½á ´ÜÀÏ ¼¼Æ÷ ºÐ¼® ±â¼úÀ» °ÈÇÏ°í ¼¼Æ÷ ¼±º° ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄ×½À´Ï´Ù.
·¯½Ã¾Æ¿Í ¿ìÅ©¶óÀ̳ªÀÇ ÀüÀïÀÌ ¼¼Æ÷ ¼±º° ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº º¹ÀâÇÏ°í ´Ù¸éÀûÀÔ´Ï´Ù. ºÐÀï°ú ±× ¿©ÆÄ·Î ÀÎÇØ ¿µÇâÀ» ¹Þ´Â Áö¿ªÀÇ ÀÇ·á ÀÎÇÁ¶ó ±¸Ãà¿¡ ÇÊ¿äÇÑ ÀÚ¿ø, °ü½É, ÀÚ±ÝÀÌ Àü¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ¼¼Æ÷ ¼±º°°ú °°Àº ÷´Ü ±â¼úÀÌ ÀÇ·á ¹× ¿¬±¸ ºÐ¾ß¿¡¼ äÅÃµÇ°í »ç¿ëµÇ´Â ¹æ½Ä¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
The Global Cell Sorting Market reached US$ 236.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 389.8 million by 2030. The Global Cell Sorting Market is expected to exhibit a CAGR of 6.6% during the forecast period 2023-2030.
Cell sorting has numerous applications in research, clinical diagnostics, and therapeutics. It makes it possible to separate rare cell groups, including stem cells or circulating tumor cells, for further analysis. Additionally, it makes it easier to purify particular cell types for therapeutic uses like developing cell-based medicines or researching immune cell populations.
However, the high cost of devices, stringent regulations, lack of skilled personnel and lack of awareness of cell sorting technology in developing countries are some factors hindering the growth of the cell sorting market.
Nearly 60% of American adults suffer from at least one chronic illness. The major causes of death in the US include chronic diseases like diabetes, cancer, and cardiovascular disease. Heart disease, cancer, stroke, chronic obstructive pulmonary disease, and diabetes account for over two-thirds of all fatalities.
According to the CDC, 90% of the nation's $3.8 trillion in annual healthcare costs are attributable to persons with chronic illnesses and mental health issues. According to a recent report by the Partnership to Fight Chronic Disease, by 2030, the expense of treating the seven most prevalent chronic diseases in the United States will total $2 trillion annually or $8,600 per person. According to the same report, reducing harmful behaviors might prevent 1,100,000 deaths annually.
One of the largest industries in America is biopharma, which is worth billions of dollars annually and is crucial to the American economy and the patients who use their products. This business is experiencing tremendous expansion due to the emergence of CDMO Biologics companies, which are generating pharmaceuticals more quickly than before.
The expansion of this industry is also attributed to an expanding world population. The demand from the world's population has increased pressure on the biopharma business, but it has also allowed it to attract more investment, increase profitability, and expand.
With personalized medicine, it's possible to transform a "one size fits all" approach to diagnosis, medication, and prevention into an individualized one. Targeted treatments based on unique patient traits are the goal of personalized medicine. Identifying and isolating particular cell types for customized therapeutics depend heavily on cell sorting technology. The demand for cell sorting technology is anticipated to rise as personalized medicine grows.
The COVID-19 pandemic has had a positive impact on the cell sorting market. The variability of the immune response and the effects of COVID-19 on various cell types have been extensively studied using single-cell analytic techniques, including cell sorting. The pandemic has enhanced single-cell analysis techniques and increased demand for cell sorting technology by highlighting the need to comprehend individual cells' traits and reactions.
The impact of the Russia-Ukraine war on the cell sorting market is complex and multifaceted. Resources, attention, and finance for the construction of healthcare infrastructure in the impacted areas may be diverted by the conflict and its aftermath. This might affect how cutting-edge technologies, like cell sorting, are adopted and used in healthcare and research contexts.
The Global Cell Sorting Market is segmented based on technology, product and services, application, End-user, and region.
The fluorescence-activated cell sorting (FACS) segment accounted for the highest market stake, accounting for approximately 43.6% of the cell sorting market in 2022. The flow cytometry technique, fluorescence-activated cell sorting (FACS), is specialized. Using the unique light scattering and fluorescence properties of each cell, it offers a way for dividing a heterogeneous mixture of living cells into two or more containers, one cell at a time.
It is a practical scientific tool since it allows for the quick, accurate, and quantitative recording of fluorescence signals from individual cells as well as the physical segregation of cells of specific interest.
North America is expected to dominate the cell sorting market, accounting for around 39.6%. The market player applies strategies such as product launches and collaboration to expand their business.
For instance, in January 2023, Thermo Fisher Scientific, the leader in serving science, launched the Bigfoot Spectral Cell Sorter in India. The groundbreaking cell sorting system combines spectral sorting and analysis with traditional sorting to produce quick, simple-to-use cell sorting.
The major global players in the market include: Bio-Rad Laboratories, Inc., Sony Biotechnology Inc., BD, Merck KGaA, Danaher Corporation, Miltenyi Biotec GmbH, Affymetrix, Inc., Sysmex Partec GmbH, On-Chip Biotechnologies Co., Ltd., Thermo Fisher Scientific among others.
The Global Cell Sorting Market Report Would Provide Approximately 69 Tables, 70 Figures And 195 pages.
LIST NOT EXHAUSTIVE